RecruitingNot ApplicableNCT07115953

Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension

Sub-study of SPYRAL AFFIRM: Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT)


Sponsor

Medtronic Vascular

Enrollment

130 participants

Start Date

Sep 22, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of the SPYRAL SWYFT sub-study is to evaluate whether renal denervation with the Symplicity Spyral system performed in the main and first order branch renal arteries yields a shorter procedure time and is as effective in reducing blood pressure than the procedural approach used in the SPYRAL HTN-ON MED and SPYRAL PIVOTAL - SPYRAL HTN-OFF MED clinical studies in an uncontrolled hypertensive population.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Individual is diagnosed with hypertension and has a baseline office systolic blood pressure ≥140 mmHg
  • Individual has a baseline office diastolic blood pressure ≥ 90 mmHg
  • Individual has an average systolic baseline home blood pressure ≥135 mmHg (with ≥7 days of valid pre-procedure measurements)
  • Individual has a valid 24-hour Ambulatory Blood Pressure Measurement at baseline

Exclusion Criteria9

  • Individual lacks appropriate renal artery anatomy
  • Individual has undergone prior renal denervation
  • Individual has a documented condition that would prohibit or interfere with ability to obtain an accurate blood pressure measurement
  • Individual requires chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea
  • Individual has an estimated glomerular filtration rate (eGFR) of \<45 mL/min/1.73m2
  • Individual has one or more episode(s) of orthostatic hypotension
  • Individual is pregnant, nursing or planning to become pregnant
  • Individual has documented primary pulmonary hypertension
  • Individual has documented type 1 diabetes mellitus or poorly-controlled type 2 diabetes mellitus with glycosylated hemoglobin greater than 8.0%

Interventions

DEVICESymplicity Spyral™ multi-electrode renal denervation system

After a renal angiography according to standard procedures, subjects are treated with the renal denervation procedure.


Locations(19)

The Alfred Hospital

Melbourne, Australia

Royal Perth Hospital

Perth, Australia

Ziekenhuis Oost Limburg - Campus Sint-Jan

Genk, Limburg, Belgium

CHC MontLégia

Liège, Liège, Belgium

Algemeen Stedelijk Ziekenhuis - Campus Aalst

Aalst, Belgium

AZ Sint Jan Brugge-Oostende av

Bruges, Belgium

Universitair Ziekenhuis Gent

Ghent, Belgium

Universitat des Saarlandes

Homburg, Saarland, Germany

Sana Kliniken Lübeck GmbH

Lübeck, Schleswig-Holstein, Germany

Universitätsklinikum Erlangen

Erlangen, Germany

Leipzig Heart Institute

Leipzig, Germany

Schwarzwald-Baar Klinikum Villingen-Schwenningen

Villingen-Schwenningen, Germany

Mater Misericordiae University Hospital

Dublin, Dublin, Ireland

Sarawak Heart Center

Kota, Malaysia

Zuyderland Medisch Centrum Heerlen

Heerlen, Netherlands

Erasmus University Medical Center

Rotterdam, Netherlands

MacKay Memorial Hospital, Tamsui Branch

Taipei, Taiwan

National Taiwan University Hospital

Taipei, Taiwan

Oxford University Hospitals NHS Trust - John Radcliffe Hospital

Oxford, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07115953


Related Trials